Difference between revisions of "Tenosynovial giant cell tumor"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s...") |
Warner-admin (talk | contribs) m (Text replacement - "|Phase III (" to "|Phase 3 (") |
||
| Line 29: | Line 29: | ||
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6860022/ Tap et al. 2019 (ENLIVEN)] | |[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6860022/ Tap et al. 2019 (ENLIVEN)] | ||
|2015-2016 | |2015-2016 | ||
| − | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) |
|Placebo<sup>1</sup> | |Placebo<sup>1</sup> | ||
| style="background-color:#1a9850" |Superior ORR | | style="background-color:#1a9850" |Superior ORR | ||
Revision as of 15:03, 12 February 2022
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN  ejdavis25
|
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Pexidartinib monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Tap et al. 2019 (ENLIVEN) | 2015-2016 | Phase 3 (E-RT-esc) | Placebo1 | Superior ORR |
1Patents assigned to placebo were offered open-label pexidartinib after week 24.
Targeted therapy
- Pexidartinib (Turalio) as follows:
- Cycle 1: 400 mg PO every morning and 600 mg PO every evening
- Cycle 2 onwards: 400 mg PO twice per day
14-day cycles
References
- ENLIVEN: Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019 Aug 10;394(10197):478-487. Epub 2019 Jun 19. link to original article link to PMC article contains verified protocol PubMed NCT02371369